Kronos Bio Inc (KRON)

$1.25

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $1.21
    $1.30
    $1.25
    downward going graph

    3.2%

    Downside

    Day's Volatility :7.14%

    Upside

    4.07%

    downward going graph
  • $0.69
    $2.22
    $1.25
    downward going graph

    44.8%

    Downside

    52 Weeks Volatility :68.92%

    Upside

    43.69%

    downward going graph

Returns

PeriodKronos Bio IncSector (Health Care)Index (Russel 2000)
3 Months
31.58%
5.3%
0.0%
6 Months
3.31%
6.3%
0.0%
1 Year
-36.22%
9.2%
0.0%
3 Years
-94.26%
13.1%
-19.9%

Highlights

Market Capitalization
75.1M
Book Value
$2.28
Earnings Per Share (EPS)
-1.99
Wall Street Target Price
4.13
Profit Margin
0.0%
Operating Margin TTM
-762.22%
Return On Assets TTM
-28.58%
Return On Equity TTM
-64.2%
Revenue TTM
7.6M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
106.4%
Gross Profit TTM
0.0
EBITDA
-105.9M
Diluted Eps TTM
-1.99
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.57
EPS Estimate Next Year
-1.5
EPS Estimate Current Quarter
-0.42
EPS Estimate Next Quarter
-0.4

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Kronos Bio Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 230.4%

Current $1.25
Target $4.13

Technicals Summary

Sell

Neutral

Buy

Kronos Bio Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kronos Bio Inc
Kronos Bio Inc
23.76%
3.31%
-36.22%
-94.26%
-95.38%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kronos Bio Inc
Kronos Bio Inc
NA
NA
NA
-1.57
-0.64
-0.29
NA
2.28
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kronos Bio Inc
Kronos Bio Inc
Buy
$75.1M
-95.38%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Kronos Bio Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 103.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.5% return, outperforming this stock by 287.8%

Institutional Holdings

  • Bvf Inc

    4.83%
  • Vida Ventures Advisors, LLC

    4.60%
  • Vanguard Group Inc

    3.24%
  • Millennium Management LLC

    3.04%
  • Alphabet Inc

    2.39%
  • Wildcat Capital Management, LLC

    2.16%

Company Information

kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.

Organization
Kronos Bio Inc
Employees
61
CEO
Dr. Norbert W. Bischofberger Ph.D.
Industry
Health Technology

FAQs